Mereo BioPharma Group plc 8-K/A

What Happened

• Mereo BioPharma Group plc announced its financial results for the quarter ended March 31, 2026, in a press release dated May 12, 2026. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8‑K.
• The company also amended a previously filed Form 8‑K solely to correct the item tag related to an earlier reported completion of an acquisition or disposition of assets (Item 2.01). The amendment did not change any substantive disclosure.

Key Details

• Quarter reported: Q1 ended March 31, 2026; results announced May 12, 2026.
• Press release filed as Exhibit 99.1 to the Form 8‑K (full financial details are in that release).
• Amendment to the earlier 8‑K only corrected the item tag (no change to disclosed facts).
• Report signed on behalf of the company by Christine Fox, Chief Financial Officer, dated May 12, 2026. Interactive XBRL cover page included.

Why It Matters

• The filing alerts investors that Mereo has released its quarterly results; investors should read Exhibit 99.1 (the press release) for revenue, earnings, cash position, and any operational updates or guidance.
• The amended 8‑K is a housekeeping correction: it does not alter the company’s disclosed facts about the prior transaction, so it does not represent new substantive information about mergers or asset dispositions.
• For investment decisions, focus on the detailed numbers and commentary in the press release and subsequent filings rather than the tagging correction.